As FDA begins to build policy and review biosimilar submission packages, the Senate subcommittee on Primary Health and Retirement Security shows some skepticism about the time delay and difficulties that have emerged. Janet Woodcock, director of the Center for Drug Evaluation and Research (CDER), responded by addressing the importance of getting the science right for the release of the first biosimilars. Read her testimony on fda.gov from September 17, 2015 here. When asked about the education of biosimilars to medical professionals, she said that they’ve “laid out a plan of education campaigns and still need to determine what people need to know.” To read more in an article on raps.org, click here.